MX2016013741A - Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. - Google Patents

Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Info

Publication number
MX2016013741A
MX2016013741A MX2016013741A MX2016013741A MX2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A MX 2016013741 A MX2016013741 A MX 2016013741A
Authority
MX
Mexico
Prior art keywords
parkinson
patient
disease
rapid relief
motor fluctuations
Prior art date
Application number
MX2016013741A
Other languages
English (en)
Spanish (es)
Inventor
Michael M Lipp
Martin Freed
Richard P Batycky
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of MX2016013741A publication Critical patent/MX2016013741A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2016013741A 2014-04-21 2014-04-21 Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson. MX2016013741A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Publications (1)

Publication Number Publication Date
MX2016013741A true MX2016013741A (es) 2017-04-06

Family

ID=54332876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013741A MX2016013741A (es) 2014-04-21 2014-04-21 Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.

Country Status (14)

Country Link
US (2) US20170296498A1 (enExample)
EP (2) EP3134077A4 (enExample)
JP (1) JP2017513866A (enExample)
KR (2) KR20210144946A (enExample)
CN (2) CN106659685B (enExample)
AU (2) AU2014391721B2 (enExample)
BR (1) BR112016024502A8 (enExample)
CA (1) CA2946165C (enExample)
IL (2) IL309959A (enExample)
MX (1) MX2016013741A (enExample)
RU (1) RU2698330C2 (enExample)
SG (1) SG11201608608PA (enExample)
WO (1) WO2015163840A1 (enExample)
ZA (1) ZA201607833B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
KR20200118033A (ko) * 2018-01-05 2020-10-14 임펠 뉴로파마 인코포레이티드 정밀 후각기관 장치에 의한 레보도파 분말의 비강내 전달
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
SI2630954T1 (sl) 2002-03-20 2017-02-28 Civitas Therapeutics, Inc. Pulmonalno dovajanje za levodopo
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
EP2320892A2 (en) * 2008-06-30 2011-05-18 Novartis AG Combination products
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
HK1212623A1 (zh) * 2012-10-22 2016-06-17 丝维塔斯治疗公司 用於快速緩解帕金森病的左旋多巴製劑
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Also Published As

Publication number Publication date
KR20170008754A (ko) 2017-01-24
CN106659685A (zh) 2017-05-10
WO2015163840A1 (en) 2015-10-29
RU2698330C2 (ru) 2019-08-26
RU2016144340A (ru) 2018-05-22
AU2020239754A1 (en) 2021-01-14
EP3831375A1 (en) 2021-06-09
RU2016144340A3 (enExample) 2018-05-22
US20170296498A1 (en) 2017-10-19
ZA201607833B (en) 2018-08-29
JP2017513866A (ja) 2017-06-01
BR112016024502A8 (pt) 2021-06-29
IL309959A (en) 2024-03-01
BR112016024502A2 (pt) 2017-08-15
KR20210144946A (ko) 2021-11-30
AU2014391721A1 (en) 2016-11-03
SG11201608608PA (en) 2016-11-29
IL248445A0 (en) 2016-12-29
EP3134077A1 (en) 2017-03-01
EP3134077A4 (en) 2017-12-20
CN113209055A (zh) 2021-08-06
CA2946165A1 (en) 2015-10-29
CA2946165C (en) 2022-10-18
US20230053976A1 (en) 2023-02-23
AU2020239754B2 (en) 2022-06-23
CN106659685B (zh) 2021-02-05
AU2014391721B2 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2021001091A (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington.
SA521421115B1 (ar) عقاقير أولية من كربيدوبا وليفودوبا وطرق الاستخدام
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
PH12018501072A1 (en) Modified release orally administered amino acid formulations
MX2015015249A (es) Peptidos terapeuticos.
MX351508B (es) Sistemas y métodos para el diseño y fabricación de calzado de protección de pacientes.
TW201613636A (en) Methods of treating Alzheimer's Disease
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019000677A (es) Células miméticas de células b.
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
ZA201704327B (en) Methods and compositions for treating brain diseases
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX367321B (es) Composición para el cuidado de la piel y métodos para la misma.
MX380758B (es) Compuesto que tiene actividad inhibitoria de idh mutante, método de preparación y usos del mismo.
MX2016013741A (es) Rápido alivio de las fluctuaciones motoras en la enfermedad de parkinson.
WO2014111790A3 (en) Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
MY202857A (en) Method of treating hyperglycemia
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
HK1235011A1 (en) Rapid relief of motor fluctuations in parkinson's disease
WO2014006571A3 (en) Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof
WO2018026776A3 (en) Foxm1 modulators and uses thereof